Skip to content

美利医疗系统

US · MMSI #2114 按市值排名 上市于 1970
89.20 -0.37 -0.41%
实时 - 追踪5344个代码 - 心跳于467秒前 · 2026-10-16 19:30

✦ 量化合理价值 计算方式说明

接近合理价值
76.49 合理价值 ≈ 112.10 147.70
  • 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为76.49-147.70。
  • 当前价格比按平均倍数计算的合理价值(112.10)低20.4%。

估值 各估值倍数与自身5年区间的对比

市净率 3.01 低于历史水平 第12百分位
5年平均 3.55 · 在Medical Instruments & Supplies中排名第26/51
市盈率 34.82 低于历史水平 第8百分位
5年平均 52.63 · 前瞻 28.04 · 在Medical Instruments & Supplies中排名第15/27
市销率 3.20 低于历史水平 第23百分位
5年平均 3.54 · 前瞻 3.00 · 在Medical Instruments & Supplies中排名第31/51

同业对比 Medical Instruments & Supplies

公司 市值 市盈率(TTM) 市净率 股息率
美利医疗系统 (MMSI) 5.33B 36.71 3.17 0.00%
Intuitive Surgical (ISRG) 150.74B 48.93 8.30 0.00%
Becton Dickinson & Co (BDX) 52.23B 57.93 2.14 2.19%
ResMed (RMD) 33.61B 22.91 5.10 1.00%
Alcon (ALC) 31.99B 50.52 1.48 0.53%
Medline (MDLN) 31.55B 68.24 2.73 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★★ 合理价值99.09 经济护城河Narrow 不确定性Low

当前股价低于晨星合理价值估算11.1%。

合理价值

Merit Medical Systems Inc is assigned a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 12% discount to our quantitative fair value estimate of $99.09 per share, which is reinforced by this estimate's low uncertainty rating.

The firm's solid growth strengthens our estimated fair value. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's EPS 5-year growth of 13.3% sits in the top 40% compared with global peers. The robust five-year track record of EPS growth is reason to be optimistic about the firm's shares. We believe this is a sign that shares could be cheap.

Conversely, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.1, a core component of valuation, sits in the top 50% compared with global peers. The market value of equity is low relative to the business' enterprise value, suggesting the company could be buried in debt if anything goes wrong. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

经济护城河

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

美利医疗系统 讨论区 0 条评论

发表评论